A re-assessment of 4CMenB vaccine effectiveness against serogroup B invasive meningococcal disease in England based on an incidence model

被引：0
|
作者：
Lorenzo Argante
Victoria Abbing-Karahagopian
Kumaran Vadivelu
Rino Rappuoli
Duccio Medini
机构：
[1] GSK,
[2] GSK,undefined
来源：
BMC Infectious Diseases | / 21卷
关键词：
Invasive meningococcal disease; IMD; MenB; 4CMenB; Bexsero; Effectiveness; VE; Incidence model; Screening method; Epidemiology;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Use of a multicomponent, recombinant, meningococcal serogroup B vaccine ( 4CMenB) for bacterial meningitis prevention
    Esposito, Susanna
    Castellazzi, Luca
    Bosco, Annalisa
    Musio, Alessandra
    Stoddard, Jeffrey
    IMMUNOTHERAPY, 2014, 6 (04) : 395 - 408
  • [22] Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study
    Parikh, Sydel R.
    Andrews, Nick J.
    Beebeejaun, Kazim
    Campbell, Helen
    Ribeiro, Sonia
    Ward, Charlotte
    White, Joanne M.
    Borrow, Ray
    Ramsay, Mary E.
    Ladhani, Shamez N.
    LANCET, 2016, 388 (10061): : 2775 - 2782
  • [23] A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program
    O'Ryan, Miguel
    Stoddard, Jeffrey
    Toneatto, Daniela
    Wassil, James
    Dull, Peter M.
    DRUGS, 2014, 74 (01) : 15 - 30
  • [24] A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program
    Miguel O’Ryan
    Jeffrey Stoddard
    Daniela Toneatto
    James Wassil
    Peter M. Dull
    Drugs, 2014, 74 : 15 - 30
  • [25] Safety and immunogenicity of co-administered meningococcal serogroup B (4CMenB) vaccine: A literature review
    Abitbol, Veronique
    Sohn, Woo-Yun
    Horn, Michael
    Safadi, Marco Aurelio P.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (02)
  • [26] The multicomponent meningococcal serogroup B vaccine (4CMenB): origin, composition, health impact and unknown aspects
    Mameli, Chiara
    Galli, Erica
    Mantegazza, Cecilia
    Fabiano, Valentina
    Zuccotti, Gian Vincenzo
    FUTURE MICROBIOLOGY, 2015, 10 (10) : 1579 - 1598
  • [27] Modeling the persistence of 4CMenB vaccine protection against real world meningococcal B disease in adolescents
    Argante, Lorenzo
    Prunas, Ottavia
    Medini, Duccio
    Ypma, Ellen
    NPJ VACCINES, 2024, 9 (01)
  • [28] Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease
    Stefan Scholz
    Magdalena Schwarz
    Ekkehard Beck
    Kinga Meszaros
    Melanie Schneider
    Bernhard Ultsch
    Wolfgang Greiner
    Infectious Diseases and Therapy, 2022, 11 : 367 - 387
  • [29] Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease
    Scholz, Stefan
    Schwarz, Magdalena
    Beck, Ekkehard
    Meszaros, Kinga
    Schneider, Melanie
    Ultsch, Bernhard
    Greiner, Wolfgang
    INFECTIOUS DISEASES AND THERAPY, 2022, 11 (01) : 367 - 387
  • [30] Progressive Decrease in the Potential Usefulness of Meningococcal Serogroup B Vaccine (4CMenB, Bexsero®) in Gipuzkoa, Northern Spain
    Perez-Trallero, Emilio
    Esnal, Olatz
    Marimon, Jose M.
    PLOS ONE, 2014, 9 (12):
12345